ACTRN12607000262404已完成2 期
The Efficacy and Safety of Treatment with Intravitreal Ranibizumab in Patients with Branch Retinal Vein Occlusion.
Associate Professor Ian McAllister0 个研究点目标入组 40 人开始时间: 2007年5月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Macular oedema in the study eye with the following characteristics:a. Due to BRVO.b. Involving the centre of the fovea.c. Duration 6 week to 9 months prior to baseline visit.d. Visual acuity reduction attributable to the oedema where the macula is non-ischaemic (<50% ischaemic injury to the perifoveolae vascular zone).2. Best corrected visual acuity (BCVA) score as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline between 20 letters and 68 letters (approximately 20/50 to 20/400 Snellen visual acuity). 3. Central macular oedema as measured by OCT at baseline to exceed 250 um. 4. Clear ocular media and adequate pupillary dilation.5. Written informed consent.6. Ability to return for all study visits.
排除标准
- •1.Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding.2. Known sensitivity to study drug(s) or class of study drug(s).3. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required). 4. Use of any other investigational agent in the last 30 days.5. Any other ocular condition in the study eye that would prevent improvement in visual acuity, e.g., macular ischaemia, underlying macular degeneration, epi-retinal membrane.6. Neovascularisation of the iris, disc or retina.7. Previous treatment with intravitreal corticosteriods, intravitreal anti-VEGF agents or macular grid laser in previous 3 months.8. Aphakia or presence of anterior chamber lens in the study eye.9. Significant media opacities such as cataract.10. Previous pars plana vitrectomy.11. History of retinal detachment or surgery for retinal detachment.12. Any condition which would preclude a patient's ability to comply with the study requirements or to be available for the duration of the study.13. BRVOs that have more than 10-disc diamteres of capillary non perfusion.14. Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, sclertitis, endoophthalmitis as well as idiopathic or autoimmune-associated uveitis in either eye.15. Presence of a retinal pigment epithelial tear involving the macula in the study eye.16. Any evidence of significant AMD in the study eye.17. Extra capsular extraction of cataract with phacoemulsification within 3 months preceding baseline, or a history of post-operative complications within the last 12 months preceding baseline in the study eye (uveitis, cyclitis etc).18. Contra indication to pupil dilation in either eye.
研究者
相似试验
已完成
不适用
Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000005691Department of Ophthalmology, Shiga University of Medical Science40
已完成
不适用
Evaluation of the efficacy and safety of intravitreal bimonthly injection of aflibercept for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000010312Department of Ophthalmology, Shiga University of Medical Science40
招募中
3 期
Evaluation of efficacy of recombinant Tissue Plasminogen Activator on facility of vitrectomy for diabetic Tractional Retinal DetachmentIRCT20200217046522N1Iran University of Medical Sciences38
尚未招募
4 期
Efficacy and Saftey of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled TrialCTRI/2020/02/023125Department of Obstetrics And Gynecology
进行中（未招募）
1 期
Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency AnemiaEUCTR2019-003821-70-PLAmerican Regent, Inc.10